Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexahydrocurcumin is a natural diarylheptanoid compound and a major active metabolite of curcumin. It is found in plants such as Zingiber officinale (ginger). Hexahydrocurcumin acts as a selective and orally active cyclooxygenase-2 (COX-2) inhibitor with no significant activity against COX-1. It exhibits potent antioxidant, anti-inflammatory, and anticancer properties. Mechanistically, it reduces prostaglandin E2 production by downregulating COX‑2 expression and modulates oxidative stress pathways by activating nuclear factor erythroid 2-related factor 2 (NRF2), enhancing cellular antioxidant defenses. Preclinical studies suggest potential therapeutic applications in cancer (notably colon and breast cancer), retinal degenerative diseases such as age-related macular degeneration (AMD), and other conditions associated with inflammation or oxidative stress[1][3][4][5][7][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hexahydrocurcumin.